net debt total capit
medic suppli devic
sale
reason report
strong quarter guid move higher pt
bottom line deliv anoth quarter
out-performance driven larg intern -- encourag follow
misstep overal sale growth acceler quarter --
despit face
toughest compar even importantli view
rais sale guidanc beat --
vs previous -- midpoint vs
beat vs consensu beat vs midpoint quarterli
guidanc rang still friday stock move tough call print
given omnipod sale -- y/i -- came
consensu low end guidanc rang manag
effect lower omnipod sale guidanc albeit less
quantifi appear intern
sale may seen less headwind inventori
destock guid call could
contribut intern beat horizon integr pump/
cgm push late though
part due approv phone control -- major posit view
share sell friday believ present
even attract entri point investor despit small nitpick
one might see clear line sight growth acceler
next year dash roll shift
busi pharmaci reduc barrier
adopt could also drive higher attrit benefit
full year direct distribut europ enter
type market -- doubl -- possibl
reiter op pt pt -- -- appli
ev/sal multipl sale estim now-
lower pt still reflect upsid also take account
believ bit re-rat smid-cap med-tech growth stock
multipl share current trade sale
estim expect multipl hold current level given
believ sustain double-digit growth next year
path profit key issu smid-cap med-tech investor
believ share deserv trade premium ev/
sale multipl smid-cap med-tech coverag univers
outlook move higher still conserv clearli
consist track drive strong double-digit global instal base
growth -- guid -- compani
benefit improv sale rep support execut leverag
clinic data continu evolv technolog
sale estim move
compani inform leerink partner llc research
revenu ep figur includ fa option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target next
year continu focu drive strong referr momentum increas sale
forc product greater awar deliv believ around top-
line compound-annual-growth-rate time-frame ex neighborhood diabet underw
manag transit four year ago busi stabilized-to-acceler
believ long-term market opportun pump therapi unchang
penetr type patient today solid execut continu
reinvest sale forc appear pois drive sustain re-acceler
new patient add beyond diabet compani meaning opportun platform
drug deliveri technolog non-insulin sale underway expect ramp
least total sale next year base estim
continu rate share op pt appli ev/sal multipl
sale estim pt reflect upsid also take account
believ bit re-rat smid-cap med-tech growth stock multipl
share current trade sale estim expect multipl hold
current level given believ sustain double-digit growth next year
path profit key issu smid-cap med-tech investor believ share
deserv trade premium ev/sal multipl smid-cap med-tech coverag
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt leerink partner estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt leerink partner estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report leerink partner estim
increas
dexcom cgm
autom insulin deliveri
essenti enabl omnipod
cgm speak one
clinic trial on-go
august stare studi enrol
patient expect complet octob
august expect complet trial
move final pre-pivot
start
enrol complet
believ possibl present data
ada
may expect data avail
run clinic trial
full control
actual
market two decad
good deliveri
system avail eli lilli
launch kwikpen late
pump avail market u-
effect
increas capac
reservoir enabl omnipod
better serv peopl higher
insulin requir peopl
live insulin depend type
diabet omnipod
omnipod doubl
